organization · Reporting owner
Forbion III Management B.V.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| enGene Therapeutics Inc.ENGN · Entity 6638 | 10% owner | October 31, 2023 | November 13, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
enGene Therapeutics Inc.
Report date October 31, 2023 · Filed November 13, 2023
Jointly reported with Forbion Capital Fund III Cooperatief U.A.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common sharesSEC Table I · non-derivative | Direct | 2,894,735 |
Reported balance
Holding disclosure · report date 2023-10-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,894,735 F1: The securities are held directly by Forbion Capital Fund III Cooperatief U.A. ("Forbion III COOP"). Forbion III Management B.V. ("Forbion III") is the director of Forbion III COOP and disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2028-10-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-10-31 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The securities are held directly by Forbion Capital Fund III Cooperatief U.A. ("Forbion III COOP"). Forbion III Management B.V. ("Forbion III") is the director of Forbion III COOP and disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are held directly by Forbion Capital Fund III Cooperatief U.A. ("Forbion III COOP"). Forbion III Management B.V. ("Forbion III") is the director of Forbion III COOP and disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
No transactions match
Try broader filters. Historical coverage is still being backfilled.
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.